The combination of OCT and MRI can help provide an improved sense of clarity when managing MINOCA patients, according to new data presented at ACC.26 in New Orleans.
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.
The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications.
Insured or not, few Americans are immune to medical debt. And when a budget-busting event comes, it can significantly worsen such basic social determinants of health (SDOH) as housing security and food affordability.
The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough.
This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.
The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.
Briefly trained in point-of-care cardiac ultrasound, 72% of second-year medical students obtained clinical-quality views from a mannequin and 61% made the correct diagnosis in a volunteer simulated patient.
